Gilead Sciences has received a highly anticipated approval from the FDA for its long-acting HIV prevention injection, YEZTUGO (lenacapavir), marking a significant advancement in HIV prevention. On June 18, 2025, the FDA approved YEZTUGO, an injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 35 kg to help prevent sexually transmitted HIV.
This makes YEZTUGO the first and only PrEP option in the US that is administered just twice a year. YEZTUGO becomes the second long-acting PrEP drug available on the market, alongside GSK and ViiV’s Apretude, which received FDA approval in 2021 for bi-mont...
